NASDAQ · Analyst Forecast

Vertex Pharmaceuticals Incorporated (VRTX) Stock Forecast & Price Target

$534.85 NASDAQ: VRTX Market Cap $135.60B

Price as of Nov 16, 2026 (intraday, delayed) · Analyst estimates retrieved Nov 12, 2026 · Source: Financial Modeling Prep (analyst estimates) (methodology)

Revenue and earnings estimates published by analysts covering Vertex Pharmaceuticals Incorporated (VRTX), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.

For Vertex Pharmaceuticals Incorporated, analysts forecast revenue rising from $11.98B in 2025 to $20.77B in 2030; the average estimate for 2030 earnings per share is $33.79; with published estimates ranging from $32.23 to $35.36; 21 analysts contribute to these figures. These are forecasts published by analysts, not results.

Analyst price targets

MeasureValue
Current priceWhat the share trades at now.$534.85
Consensus targetThe average of the price targets analysts have published.$580.20
Median targetThe middle target, less affected by a single outlier.$615.00
Highest targetThe most optimistic published target.$665.00
Lowest targetThe most pessimistic published target.$350.00
Difference from priceHow far the consensus target sits from today’s price.+8.5%

A price target is one analyst's forecast of where a share might trade, usually over twelve months. Targets are frequently revised, they disagree with each other, and they are not a measure of what a company is worth.

Revenue forecast (USD)

The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.

YearLowAverageHighAnalysts
2025$11.91B$11.98B$12.04B20
2026$13.19B$13.26B$13.29B21
2027$14.23B$14.72B$15.28B19
2028$15.01B$16.58B$18.13B20
2029$18.07B$18.73B$19.40B10
2030$20.03B$20.77B$21.50B10

Earnings per share forecast

YearLowAverageHighAnalysts
2025$17.96$18.48$18.8020
2026$17.69$18.19$19.2121
2027$18.28$20.11$21.6219
2028$16.72$24.18$32.2220
2029$28.17$29.53$30.9010
2030$32.23$33.79$35.3610

Vertex Pharmaceuticals Incorporated (VRTX) forecast — frequently asked questions

What is the analyst price target for Vertex Pharmaceuticals Incorporated?

Analysts covering Vertex Pharmaceuticals Incorporated (VRTX) have a consensus price target of $580.20, 8.5% above the current price of $534.85. Published targets range from $350.00 to $665.00. A price target is a forecast, not a measure of value, and targets are revised often.

What are analysts forecasting for Vertex Pharmaceuticals Incorporated's earnings?

The average analyst estimate for Vertex Pharmaceuticals Incorporated (VRTX) earnings per share in 2030 is 33.79, with individual estimates between 32.23 and 35.36.

How much revenue is Vertex Pharmaceuticals Incorporated expected to make?

Analysts forecast Vertex Pharmaceuticals Incorporated (VRTX) revenue of $20.77B in 2030, based on 10 published estimates.

How many analysts cover VRTX?

21 analysts contribute estimates for Vertex Pharmaceuticals Incorporated (VRTX). Thin coverage makes an average less reliable.

Analyst forecasts for other Biotechnology stocks

REGN forecastMRNA forecastRVMD forecastROIV forecastINSM forecastUTHR forecastINCY forecastALNY forecastASND forecastEXEL forecastAll Biotechnology stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.